This document is a patent application, not a regulatory rule or guidance. It describes novel bispecific antibodies or antigen-binding fragments thereof that are designed to specifically bind to two distinct antigens with different binding affinities. The application details the inventors and provides CPC classifications related to antibodies and their therapeutic uses, particularly in treating cancer.

As this is a patent application, it does not impose direct regulatory obligations on companies. However, it may impact future research and development in the biotechnology and pharmaceutical sectors by potentially granting exclusive rights to the inventors for the described technology. Companies operating in this space should monitor patent filings for potential intellectual property considerations and competitive landscape changes.